554 / 1631
Early Relapse of Follicular Lymphoma After Rituximab Plus CHOP Defines
Patients at High Risk for Death: An Analysis From the National LymphoCare
Study. Casulo C et al J Clin Oncol. 2015 Aug 10;33(23):2516-22
• 588 patients,
19% (n = 110) had early POD
, 71% (n = 420) in reference group, 8% (n
= 46) were lost to follow-up, and 2% (n = 12) died without POD less than 2 years after
diagnosis.
• Five-year overall survival was lower in the early-POD group than in the reference
group (50% v 90%).
Trend maintained after adjusted for FLIPI (HR 6.44; 95% CI, 4.33
to 9.58). Results were similar for the validation set (FL IPI-adjusted hazard ratio,
19.8).
• Patients with FL who received first-line R-CHOP, POD within 2 years
after diagnosis
associated with poor outcomes and should be further validated as a standard end
point of chemo-immunotherapy trials of untreated FL.
This high-risk FL population warrants further study in directed
prospective clinical trials